Search Results for: NF2

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel DRG1 developmentally regulated GTP binding protein 1
Novel LIF LIF interleukin 6 family cytokine
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
Novel OSM oncostatin M
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
Novel PCNA proliferating cell nuclear antigen
  • Translesion synthesis by REV1
  • Recognition of DNA damage by PCNA-containing replication complex
  • Translesion Synthesis by POLH
  • Transcription of E2F targets under negative control by DREAM complex
  • Polymerase switching on the C-strand of the telomere
  • Processive synthesis on the C-strand of the telomere
  • Telomere C-strand (Lagging Strand) Synthesis
  • Removal of the Flap Intermediate from the C-strand
  • SUMOylation of DNA replication proteins
  • Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • PCNA-Dependent Long Patch Base Excision Repair
  • Translesion synthesis by POLK
  • Translesion synthesis by POLI
  • Termination of translesion DNA synthesis
  • HDR through Homologous Recombination (HRR)
  • Gap-filling DNA repair synthesis and ligation in GG-NER
  • Dual Incision in GG-NER
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Polymerase switching
  • Removal of the Flap Intermediate
  • Processive synthesis on the lagging strand
  • G1/S-Specific Transcription
  • E3 ubiquitin ligases ubiquitinate target proteins
  • Liothyronine
  • Acetylsalicylic acid
AGAP2 ArfGAP with GTPase domain, ankyrin repeat and PH domain 2
  • Netrin-1 signaling
AKT1 AKT serine/threonine kinase 1
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • MTOR signalling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • eNOS activation
  • AKT-mediated inactivation of FOXO1A
  • Integrin signaling
  • Deactivation of the beta-catenin transactivating complex
  • CD28 dependent PI3K/Akt signaling
  • CTLA4 inhibitory signaling
  • G beta:gamma signalling through PI3Kgamma
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • Extra-nuclear estrogen signaling
  • Negative regulation of NOTCH4 signaling
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • ATP
  • Arsenic trioxide
  • Genistein
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Resveratrol
  • Archexin
  • Enzastaurin
  • Perifosine
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
AMOT angiomotin
AMOTL2 angiomotin like 2
  • Signaling by Hippo
ARAF A-Raf proto-oncogene, serine/threonine kinase
  • RAF activation
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by MRAS-complex mutants
  • ATP
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
ARNT aryl hydrocarbon receptor nuclear translocator
  • Regulation of gene expression by Hypoxia-inducible Factor
  • PPARA activates gene expression
  • Phase I - Functionalization of compounds
  • Endogenous sterols
  • Xenobiotics
  • Aryl hydrocarbon receptor signalling
AURKA aurora kinase A
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Regulation of PLK1 Activity at G2/M Transition
  • SUMOylation of DNA replication proteins
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • AURKA Activation by TPX2
  • Interaction between PHLDA1 and AURKA
  • Phosphonothreonine
  • AT9283
  • CYC116
  • Alisertib
  • SNS-314
  • Cenisertib
  • Enzastaurin
  • 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
  • AKI-001
  • 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea
  • 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea
  • N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE
  • N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide
  • 2-(1H-pyrazol-3-yl)-1H-benzimidazole
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • Fostamatinib
  • MLN8054
BDKRB1 bradykinin receptor B1
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Ramipril
  • Captopril
  • Zinc
  • Enalaprilat
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
BECN1 beclin 1
  • Macroautophagy
  • Ub-specific processing proteases
  • Translation of Replicase and Assembly of the Replication Transcription Complex
  • Translation of Replicase and Assembly of the Replication Transcription Complex
  • Estradiol
  • Estradiol acetate
  • Estradiol benzoate
  • Estradiol cypionate
  • Estradiol dienanthate
  • Estradiol valerate
BYSL bystin like
  • Major pathway of rRNA processing in the nucleolus and cytosol
CBLC Cbl proto-oncogene C
CCNB1IP1 cyclin B1 interacting protein 1
CCND2 cyclin D2
  • Cyclin D associated events in G1
  • Regulation of RUNX1 Expression and Activity
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Testicular cancer
CCNE1 cyclin E1
  • G0 and Early G1
  • SCF(Skp2)-mediated degradation of p27/p21
  • DNA Damage/Telomere Stress Induced Senescence
  • Association of TriC/CCT with target proteins during biosynthesis
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • Cyclin D associated events in G1
  • p53-Dependent G1 DNA Damage Response
  • PTK6 Regulates Cell Cycle
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • RHOBTB3 ATPase cycle
  • Laryngeal cancer
  • Gastric cancer
CD44 CD44 molecule (Indian blood group)
  • Degradation of the extracellular matrix
  • Cell surface interactions at the vascular wall
  • Integrin cell surface interactions
  • Hyaluronan uptake and degradation
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Bivatuzumab
  • Hyaluronic acid
  • Gastric cancer
CDK4 cyclin dependent kinase 4
  • SCF(Skp2)-mediated degradation of p27/p21
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • RMTs methylate histone arginines
  • Transcriptional regulation of white adipocyte differentiation
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional regulation by RUNX2
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Purvalanol
  • Alvocidib
  • Palbociclib
  • Ribociclib
  • Abemaciclib
  • Fostamatinib
  • Glioma
  • Malignant melanoma
  • Cervical cancer

Page 1 out of 4 pages